Top Markets
#1 Pleasing Gold Pleasing Gold +1,504.59%
#2 PulseChain PulseChain +58.12%
#3 Ontology Gas Ontology Gas +36.79%
#4 Merlin's Seal BTC Merlin's Seal BTC +33.59%
#5 BOOK OF MEME BOOK OF MEME +29.82%
#6 ConstitutionDAO ConstitutionDAO +27.03%
#7 Neiro Neiro +25.72%
#8 Unit Pump Unit Pump +25.56%
#9 Pump.fun Pump.fun +25.56%
#10 Collect on Fanable Collect on Fanable +23.36%
Coin of the day
Pleasing Gold Pleasing Gold
Settings
Language
ENGLISH
Currency
USD
Theme
Surface Oncology, Inc. Surface Oncology, Inc.

Surface Oncology, Inc.

SURF
Rank in Stocks #26172
Surface Oncology, Inc. is a clinical-stage biotechnology firm focused on... Surface Oncology, Inc. is a clinical-stage biotechnology firm focused on discovering and developing innovative immuno-oncology treatments for cancer patients in the United States. Its pipeline features a range of antibody-based therapeutics, including NZV930, a fully human IgG4 monoclonal antibody designed to modulate extracellular adenosine production, and SRF617, another human IgG4 monoclonal antibody that aims to block CD39's enzymatic activity, thereby influencing adenosine levels and ATP degradation. Other key candidates include SRF388, which targets interleukin 27; GSK4381562, an antibody aimed at CD112R, an inhibitory protein found on natural killer and T cells; and SRF114, which targets the chemokine receptor CCR8. The company also maintains strategic partnerships, holding a licensing agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited for the development, manufacturing, and commercialization of SRF813-targeting antibodies. Furthermore, it has a separate licensing deal with Vaccinex, Inc. concerning the development, production, and commercialization of antibodies targeting SRF114. Established in 2014, Surface Oncology, Inc. operates from its headquarters in Cambridge, Massachusetts.
Share Price
$1.07
Last synced: 2023-09-12
Market Cap
$42.80M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Surface Oncology, Inc. (SURF)

Category

Healthcare
P/E ratio for Surface Oncology, Inc. (SURF)
P/E ratio as of 2026 TTM: 0
According to Surface Oncology, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Surface Oncology, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.